Master Services AgreementMaster Services Agreement • October 18th, 2013 • Cleveland Biolabs Inc • Services-commercial physical & biological research • New York
WHEREAS, CBLI and its subsidiaries has proprietary technology related to regulating cell death and involving: (i) selective sensitization of cancer cells to treatment or modulation of FACT, MYC, MRP 1, and androgen receptor expression; or (ii) using activators of Toll-like receptors (TLRs) including parasite-related agents, antibodies, peptides, viruses and small molecules to treat cancer, modulate hematopoietic stem cells or to treat effects associated with total body and local radiation exposure, cancer treatment side effects, infection, inflammation, ligation-reperfusion injuries, and wound healing; or (iii) modulation of FACT to treat microbial and fungal infections (the “CBLI Technology”).
